NCT05263999Phase 3Terminated

A Study of Itolizumab in Combination With Corticosteroids for the First-Line Treatment of Acute Graft Versus Host Disease (EQUATOR)

Study sponsor: Equillium

Primary completion is the date data collection ends for the main study measures, not when results are published.

Primary completion2025-04-22Actual
Enrollment · participants158Actual
Source updated2025-06-17Last update listed in the registry record

Changes to this trial

Last 12 months
Filters
Clear filters
No recorded changes are available for this view and time period. Our history may be incomplete; this does not establish that the trial stayed unchanged.

Explore older trial changes

Upgrade to Pro to see the full available history for this trial.

Upgrade to Pro Illustrative preview